← Back to list

Cergentis B.V.

Contact Details

Cergentis B.V.

Yalelaan 62, 3584 CM Utrecht

Martijn Kelder

+31-(0)30-7601636

Hotel Description

Cergentis provides services and kits based on its proprietary ‘Targeted Locus Amplification’ (TLA) technology.

TLA constitutes a paradigm shift by, uniquely, enabling targeted and complete gene sequencing. Cergentis published the TLA technology in Nature Biotechnology in 2014 (see publications). 

The TLA technology uses the physical proximity of nucleotides within a locus of interest as the basis of selection. This enables targeted complete sequencing of any locus or (trans)gene of interest and allows for detection of all single nucleotide variants (SNVs) and structural variants, for example following gene editing. 

We have applied TLA to a broad range of organisms, including human, animal, yeast and plant samples.

Cergentis works with and for leading research institutes, diagnostic labs and pharmaceutical and biotech companies globally. We provide high-throughput routine services as well as tailored services in which to be performed analyses and reports are defined in close consultation with customers.

Service projects consist of:

• TLA prep and amplification

• NGS prep and sequencing

• Data analysis

• Reporting

For more detailed information, please visit our website.

Genomics
Private
  • Industrial biotech
  • Biomedical & health
  • Agri & Food
  • Next-generation sequencing
  • Targeted sequencing
  • Genetic diagnostics
  • Bio-informatics
  • oncology
  • gene therapy
  • gene editing
  • transgenics

Expertise and Track Record

Cergentis provides services and kits based on its proprietary ‘Targeted Locus Amplification’ (TLA) technology. TLA constitutes a paradigm shift by, uniquely, enabling targeted and complete gene sequencing. We provide high-throughput routine services as well as tailored services in which to be performed analyses and reports are defined in close consultation with customers.

A long list of (co-)publications on the use of our proprietary TLA technology can be found on our website.

A long list of (co-)publications on the use of our proprietary TLA technology can be found on our website.

  • Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping, De Vree PJP et al. (2014), Nature Biotechnology
  • Sensitive Monogenic Noninvasive Prenatal Diagnosis by Targeted Haplotyping, Vermeulen C et al. (2017), Cell
  • Enhanced CHO clone screening: Applying Targeted Locus Amplification and Next-Generation Sequencing technologies during cell line development, Aeschlimann SH et al. (2019), Biotechnology Journal
  • Analytical assessment of clonal derivation of eukaryotic/CHO cell populations, Aebischer-Gumy C et al. (2018), Biotechnology Journal
  • Large-scale discovery of mouse transgenic integration sites reveals frequent structural variation and insertional mutagenesis, Goodwin LO et al. (2019), Genome Research
  • Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection, Eyquem J et al. (2017), Nature
  • Targeted Locus Amplification (TLA): A Novel Next Generation Sequencing (NGS) Technology to Detect New Molecular Markers and Monitoring Minimal Residual Disease (MRD) in Mantle Cell and Follicular Lymphoma, Genuardi E et al. (2017), Blood
  • Spectrum of genetic variants of BRCA1 and BRCA2 in a German single center study, Meisel C et al. (2017), Springer
  • Targeted Locus Amplification and Next-Generation Sequencing Hottentot, QP et al. (2016), Springer
  • Deep sequencing reveals different compositions of mRNA transcribed from the F8 gene in a panel of FVIII-producing CHO cell lines, Kaas CS et al. (2015), Biotechnology Journal

none

Hotel Characteristics

  • 25 employees

100

  • Illumina MiniSeq

none

github